HK Stock Market Move | WuXi AppTec (02359) opened more than 4% higher after reporting strong earnings. It is expected that the net profit attributable to shareholders in 2025 will increase by approximately 102.65% year-on-year.
WuXi AppTec (02359) opened more than 4% higher after the earnings exceeded expectations. As of the time of writing, it has risen by 4.69% to HK$116, with a turnover of HK$311.234 million.
WuXi AppTec (02359) opened more than 4% higher after its earnings report, and as of the time of writing, it has risen by 4.69% to HK$116, with a transaction amount of HK$311.234 million.
On the news front, on January 12th, WuXi AppTec announced that it expects the company (along with its subsidiaries collectively referred to as "the Group") to achieve an increase in operating income and net profit attributable to the company's shareholders for the year ending December 31, 2025 compared to the same period in 2024. The company expects to achieve a net profit attributable to the company's shareholders of approximately RMB 19.151 billion, an increase of approximately 102.65% year-on-year, including investment gains from the sale of equity interests in associated companies and the divestiture of certain businesses; the basic earnings per share for this period are expected to be approximately RMB 6.70 per share, an increase of approximately 104.27% year-on-year.
Related Articles
.png)
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.

HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.
HK Stock Market Move | SINO BIOPHARM(01177) rises more than 4%, management is optimistic about the prospects of VIIa being included in insurance coverage. The drug is developed by its subsidiary, Zhongda Tianqing.
.png)
HK Stock Market Move | IMMUNEONCO-B(01541) rose by more than 10% in early trading. IMM01 has been approved for clinical trials for the treatment of atherosclerosis.

Furui: Lower target price of LAOPU GOLD (06181) to 981 Hong Kong dollars. High gold prices suppress gross profit.

RECOMMEND

Patent Cliff Looms As Pharmaceutical Sector Prepares For A New Round Of Asset Competition
10/01/2026

Goldman Sachs Remains Bullish On China Equities: AI And Overseas Expansion To Drive Earnings, MSCI China Seen Rising 20% In 2026
10/01/2026

“A+H” Popularity Continues As Multiple A‑Share Companies Announce Hong Kong Listings At The Start Of The Year
10/01/2026


